EODData

MEMBERSHIP REGISTER LOG IN

FRA, 7AY1: ACTINIUM PHARMAC. DL-001

08 Sep 2026
LAST:

0.8970

CHANGE:
 0.04		OPEN:
0.8970		HIGH:
0.8970		ASK:
0.0000		VOLUME:
0
CHG(%):
4.18		PREV:
0.8610		LOW:
0.8970		BID:
0.0000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
08 Sep 260.89700.89700.89700.89700
07 Sep 260.86500.86500.86100.86100
04 Sep 260.88100.88100.88100.88100
03 Sep 260.84100.84100.84100.84100
02 Sep 260.83800.83800.83800.83800
31 Aug 260.85000.85000.85000.85000
28 Aug 260.83700.83700.83700.83700
27 Aug 260.84500.84500.84500.84500
26 Aug 260.90400.90800.90400.908011.8K
25 Aug 260.87900.87900.87900.87900

PROFILE

Name:ACTINIUM PHARMAC. DL-001
About:Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company advances two clinical stage product candidates, Actimab-A, to treat patients with myeloid malignancies including acute myeloid leukemia and myelodysplastic syndromes; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T for various blood cancer indications and gene therapies for non-malignant hematologic disorders such as sickle cell disease. It also develops ATNM-400, a preclinical non-prostate specific-membrane antigen targeting radiotherapy utilizing the Actinium-225 radioisotope for patients with prostate cancer. In addition, the company's Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). Further, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies, and its research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company is based in New York, New York.
Sector:Healthcare
Industry:Biotechnology
Address:100 Park Avenue, New York, NY, United States, 10017
Website:https://www.actiniumpharma.com
ISIN:US00507W2061

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:3.08 
Forward P/E:-0.99 
PEG Ratio:-0.05 
Price to Sales:0.83 
Price to Book:1.11 
Profit Margin:0.32 
Operating Margin:0.79 
Return on Assets:0.12 
Return on Equity:0.46 
Revenue:29.98M 
EBITDA:8.37M 
Shares:31.2M 
Market Cap:27.98M 

TECHNICAL INDICATORS

MA5:0.863.9%
MA10:0.863.9%
MA20:0.856.1%
MA50:0.8110.7%
MA100:0.900.2%
MA200:0.989.4%
STO9:84.51 
STO14:56.07
RSI14:51.64
WPR14:-43.93
MTM14:0.02
ROC14:0.02 
ATR:0.03 
Week High:0.900.0%
Week Low:0.847.0%
Month High:0.945.2%
Month Low:0.679.4%
Year High:1.4662.7%
Year Low:0.6341.5%
Volatility:28.13 

RECENT SPLITS

Date Ratio
11 Aug 20201-30